Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

NEURODEGENERATION

Tau-targeting antibody therapies: too late, wrong epitope or wrong target?

Nature Medicine volume 27, pages 1341–1342 (2021)Cite this article

Subjects

Two phase 2 studies of N-terminal tau–targeting antibody therapy fail to show clinical efficacy in progressive supranuclear palsy, despite evidence of target engagement.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Antibodies directed against tau that are currently in phase 1 or phase 2 trials in AD.

References

  1. Golbe, L. I. & Ohman-Strickland, P. A. Brain 130, 1552–1565 (2007).

    Article  Google Scholar 

  2. Dam, T. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01455-x (2021).

  3. Hoglinger, G. U. et al. Lancet Neurol. 20, 182–192 (2021).

    Article  Google Scholar 

  4. Jadhav, S. et al. Acta Neuropathol. Commun. 7, 22 (2019).

    Article  Google Scholar 

  5. Sopko, R. et al. Neurobiol. Dis. 146, 105120 (2020).

    Article  CAS  Google Scholar 

  6. Yanamandra, K. et al. Ann. Clin. Transl. Neurol. 2, 278–288 (2015).

    Article  CAS  Google Scholar 

  7. Kim, B., et al. Acta Neuropathol. https://doi.org/10.1007/s00401-021-02318-y (2021).

  8. Jabbari, E. et al. Ann. Neurol. 84, 485–496 (2018).

    Article  CAS  Google Scholar 

  9. Alzforum. https://www.alzforum.org/news/research-news/biogen-shelves-gosuranemab-after-negative-alzheimers-trial (2021).

  10. Jabbari, E. et al. Lancet Neurol. 20, 107–116 (2021).

    Article  CAS  Google Scholar 

  11. Evans, L.D. et al. Preprint at bioRxiv https://doi.org/10.1101/2020.08.11.246363 (2020).

  12. Myeku, N. et al. Nat. Med. 22, 46–53 (2016).

    Article  CAS  Google Scholar 

  13. Ji, C. & Sigurdsson, E.M. Drugs https://doi.org/10.1007/s40265-021-01546-6 (2021).

Download references

Author information

Authors and Affiliations

  1. Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK

    Edwin Jabbari

  2. Movement Disorders Centre, UCL Queen Square Institute of Neurology, London, UK

    Edwin Jabbari

  3. Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA

    Karen E. Duff

  4. UK Dementia Research Institute, University College London, London, UK

    Karen E. Duff

Authors
  1. Edwin Jabbari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen E. Duff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Edwin Jabbari or Karen E. Duff.

Ethics declarations

Competing interests

E.J. was a study-site sub-investigator in the gosuranemab trial. K.E.D. is a director and scientific board member of Ceracuity.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jabbari, E., Duff, K.E. Tau-targeting antibody therapies: too late, wrong epitope or wrong target?. Nat Med 27, 1341–1342 (2021). https://doi.org/10.1038/s41591-021-01465-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-021-01465-9

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing